Physician profile
Michael Peter Gentile, SR.
NPI 1649386020
$4,432.21
in general payments reported to CMS, 2019-2025
15 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 88% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $314 · 2021: $736 · 2022: $450 · 2023: $516 · 2024: $773 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.29 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $636.77 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $523.43 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $438.02 | 2023-2025 | Auvelity |
| Allergan, INC. | $420.82 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $415.09 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $282.92 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $233.10 | 2019-2025 | Rexulti |
| Neuronetics, INC. | $116.68 | 2019 | |
| Vanda Pharmaceuticals INC. | $99.93 | 2025 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $40.14 | 2021 | |
| Noven Therapeutics, LLC | $26.10 | 2022 | |
| Indivior INC. | $16.12 | 2022 | |
| Neurocrine Biosciences, INC. | $13.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gentile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.